Continuous Infusion of ropivacaine 0.2% — Competitive Intelligence Brief

Continuous Infusion of ropivacaine 0.2% (Continuous Infusion of ropivacaine 0.2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia/Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management Small molecule

Target snapshot

Continuous Infusion of ropivacaine 0.2% (Continuous Infusion of ropivacaine 0.2%) — University of California, San Diego. Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials and thereby producing local anesthesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continuous Infusion of ropivacaine 0.2% TARGET	Continuous Infusion of ropivacaine 0.2%	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine Ropivacaine	Lidocaine Ropivacaine	TriHealth Inc.	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
IP Lignocaine bolus and infusion	IP Lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic / Antiarrhythmic agent	Voltage-gated sodium channels
Levobupivacaine epidural bolus	Levobupivacaine epidural bolus	University of Genova	marketed	Local anesthetic (amino amide)	Voltage-gated sodium channels
Levobupivacaine PCA group	Levobupivacaine PCA group	Osijek University Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Chloroprocaine Injection [Clorotekal]	Chloroprocaine Injection [Clorotekal]	Oregon Health and Science University	marketed	Local anesthetic (ester)	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class